These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 39060201)

  • 21. Priority allocation of pandemic influenza vaccines in Australia - Recommendations of 3 community juries.
    Degeling C; Williams J; Carter SM; Moss R; Massey P; Gilbert GL; Shih P; Braunack-Mayer A; Crooks K; Brown D; McVernon J
    Vaccine; 2021 Jan; 39(2):255-262. PubMed ID: 33317870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects.
    Bok K; Sitar S; Graham BS; Mascola JR
    Immunity; 2021 Aug; 54(8):1636-1651. PubMed ID: 34348117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.
    van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP
    Front Immunol; 2021; 12():781280. PubMed ID: 34987509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hashtag as a new weapon to resist the COVID-19 vaccination policy: a qualitative study of the anti-vaccine movement in Brazil, USA, and Indonesia.
    Khadafi R; Nurmandi A; Qodir Z; Misran
    Hum Vaccin Immunother; 2022 Dec; 18(1):2042135. PubMed ID: 35240923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Community voices around COVID-19 vaccine in Chennai, India: A qualitative exploration during early phase of vaccine rollout.
    Kumar MS; Madhumathi J; Gayathri K; A Rozario AG; Vijayaprabha R; Balusamy M; Sonekar H; Panda S
    Indian J Med Res; 2022; 155(5&6):451-460. PubMed ID: 35975352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic.
    Mallapaty S
    Nature; 2021 Jun; 594(7862):161-162. PubMed ID: 34089030
    [No Abstract]   [Full Text] [Related]  

  • 28. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
    Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis.
    Hogan AB; Winskill P; Watson OJ; Walker PGT; Whittaker C; Baguelin M; Brazeau NF; Charles GD; Gaythorpe KAM; Hamlet A; Knock E; Laydon DJ; Lees JA; Løchen A; Verity R; Whittles LK; Muhib F; Hauck K; Ferguson NM; Ghani AC
    Vaccine; 2021 May; 39(22):2995-3006. PubMed ID: 33933313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Effectiveness of Global COVID-19 Vaccination Campaign.
    He D; Ali ST; Fan G; Gao D; Song H; Lou Y; Zhao S; Cowling BJ; Stone L
    Emerg Infect Dis; 2022 Sep; 28(9):1873-1876. PubMed ID: 35914516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pandemic burden in low-income settings and impact of limited and delayed interventions: A granular modelling analysis of COVID-19 in Kabwe, Zambia.
    Perez-Guzman PN; Chanda SL; Schaap A; Shanaube K; Baguelin M; Nyangu ST; Kanyanga MK; Walker P; Ayles H; Chilengi R; Verity R; Hauck K; Knock ES; Cori A
    Int J Infect Dis; 2024 Oct; 147():107182. PubMed ID: 39067669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stopping pandemics before they start: Lessons learned from SARS-CoV-2.
    Edwards AM; Baric RS; Saphire EO; Ulmer JB
    Science; 2022 Mar; 375(6585):1133-1139. PubMed ID: 35271333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in virus and immune dynamics for SARS-CoV-2 Delta and Omicron infections by age and vaccination histories.
    Tan MW; Anelone AJN; Tay AT; Tan RY; Zeng K; Tan KB; Clapham HE
    BMC Infect Dis; 2024 Jun; 24(1):654. PubMed ID: 38951848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Individual preferences for COVID-19 vaccination in China.
    Leng A; Maitland E; Wang S; Nicholas S; Liu R; Wang J
    Vaccine; 2021 Jan; 39(2):247-254. PubMed ID: 33328140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal vaccine allocation strategy: Theory and application to the early stage of COVID-19 in Japan.
    Kuniya T; Nakata T; Fujii D
    Math Biosci Eng; 2024 Jun; 21(6):6359-6371. PubMed ID: 39176429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in attitudes to vaccination as a result of the COVID-19 pandemic: A longitudinal study of older adults in the UK.
    Gallant AJ; Nicholls LAB; Rasmussen S; Cogan N; Young D; Williams L
    PLoS One; 2021; 16(12):e0261844. PubMed ID: 34941951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 vaccine and the cold chain implications for global adoption.
    Das MK
    Indian J Public Health; 2021; 65(3):307-310. PubMed ID: 34558497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opportunities to accelerate immunization progress in middle-income countries.
    Zhu J; Cole CB; Fihman J; Adjagba A; Dasic M; Cernuschi T
    Vaccine; 2024 Apr; 42 Suppl 1():S98-S106. PubMed ID: 37460357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region.
    Ortiz JR; Robertson J; Hsu JS; Yu SL; Driscoll AJ; Williams SR; Chen WH; Fitzpatrick MC; Sow S; Biellik RJ; Neuzil KM
    Vaccine; 2021 Apr; 39(15):2165-2176. PubMed ID: 33744049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.